Posted by Michael Wonder on 27 Dec 2022
Harm Reduction Therapeutics' new drug application for RiVive over the counter naloxone nasal spray accepted and granted priority review by FDA
26 December 2022 - Low cost, over the counter naloxone nasal spray advances to FDA review. Approval would increase access to this lifesaving medicine for the emergency treatment of opioid overdose.
Harm Reduction Therapeutics today announced that the FDA has accepted its new drug application for OTC RiVive (3 mg intranasal naloxone) for the emergency treatment of opioid overdose.
